Skip to search formSkip to main contentSkip to account menu

CS 917

Known as: MB-6322, MB-06322, CS-917 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites
The purpose of this analysis was to develop a population pharmacokinetic model for CS‐917, an oral hypoglycemic prodrug, and its… 
2011
2011
Contributions of hepatic gluconeogenesis suppression and compensative glycogenolysis on the glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, in non-obese type 2 diabetes…
Contributions of gluconeogenesis suppression in liver, kidney, and intestine as major gluconeogenic organs to the glucose… 
Review
2007
Review
2007
Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes.
Overproduction of glucose via gluconeogenesis is a principal cause of the high blood glucose levels found in patients with type 2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)